5 μg. Ag85A DNA vaccine was injected intramuscularly at a dosage of 100 μg. IFN-γ ELISPOT assay.  ELISPOT assay for IFN-γ was performed with ELISPOT assay kit (BD PharMingen, San Diego, CA, USA) as instructed by the manufacture. Briefly, plates were coated with the capture anti-IFN-γ monoclonal antibody (mAb) overnight at 4 °C and then blocked with complete media for 2 h at room temperature. The mice were sacrificed 2 weeks after the

final immunization. The splenocytes of five mice from each group were isolated, plated in duplicate (4 × 105 cells/well) and cultured at 37 °C for 48 h with recombinant Ag85A protein (at the final concentration of 5 μg/ml) or phytohemagglutinin (PHA) as a positive control (at the final concentration of 10 μg/ml). The plates were washed with deionized water and PBST, incubated for 2 h at room temperature after the addition of biotinylated anti-IFN-γ mAb, and then incubated for 1 h with Streptavidin-HRP. The 3-amino-9-ethylcarbazole Selleckchem ABT 888 (AEC) substrate was then added for signal development. Spots were enumerated with CTL-ImmunoSpot® S5 Micro Analyzer (Cellular Technology, Cleveland, OH, USA). Cytokine production in vitro.  Mice were

sacrificed 2 weeks after the final immunization. The splenocytes of five mice from each group were isolated, plated (4 × 105 cells/well) and cultured with Ag85A protein (5 μg/ml) or PHA (10 μg/ml) for 72 h. The concentrations of IFN-γ and interleukin (IL-4) in the culture supernatants were measured using enzyme-linked immunosorbent assay (ELISA) kit (NeoBioscience Technology Company, Shenzhen, China) following the manufacturer’s procedures. Mouse model Peptide 17 manufacturer with MDR-TB.  Seventy female BALB/c mice 6–8 weeks of age were infected intravenously with 220,000 CFU of M. tuberculosis HB361, which was resistant to RFP, isoniazid (INH) and streptomycin, but sensitive to PZA. Treatment of mouse model.  The 70 female BALB/c mice infected with MDR-TB HB361 were randomly divided into seven groups and treated as follows: Fossariinae (1) plasmid vector pVAX1 treatment

as negative control (2) RFP (Red Flag Pharmacy, Shenyang, China) treatment as negative control (3) PZA (Jing Hua Pharmacy, Chengdu, China) treatment as positive control (4) M. vaccae vaccine treatment as positive control (5) Ag85A DNA (prepared by Shanghai H&G Biotechnology Company, Shanghai, China [16]) treatment (6) RFP combined with Ag85A DNA treatment and (7) PZA combined with Ag85A DNA treatment. The mice were treated on the third day after infection. Both RFP (0.4 mg) and PZA (0.6 mg) were orally administered every day for 2 months. M. vaccae vaccine was injected intramuscularly at a dosage of 0.0075 μg for five times at 2-week intervals. Ag85A DNA vaccine was injected intramuscularly at a dosage of 100 μg for five times at 2-week intervals. Bacterial counts.  Mice were sacrificed 4 weeks after the last injection of vaccines. The lungs and spleens of the mice were taken and homogenized in saline.